Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients

Learn more about:
Related Clinical Trial
Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome Exercise and Pioglitazone for HIV-Metabolic Syndromes Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults Yoga for the Management of HIV-Metabolic Syndromes Pravastatin for Hyperlipidaemia in HIV. A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth Exercise for Patients With HIV Infections Lactate Metabolism Study in HIV Infected Persons Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells Growth Hormone Dynamics and Cardiac Steatosis in HIV The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Detraining in People Living With HIV/AIDS SHARE: Simple HAART With Abacavir, Reyataz, and Epivir The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Metabolism and Body Shape of Healthy Children and Children With Chronic Infections Changing to Nonprotease Inhibitor Treatment to Improve Side Effects Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs White Light Scanning to Aid Body Contouring: A Pilot Project Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy The Cleveland Cardiometabolic Cohort Metabolic Abnormalities in HIV-infected Persons Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients. Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Effects of Short-term Growth Hormone in HIV-infected Patients Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid Raltegravir Therapy for Women With HIV and Fat Accumulation The PREFORM Study: A Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring Effects of IGF-I in HIV Metabolic Disease Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy Effects of Growth Hormone Releasing Hormone in HIV A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy Body Composition and Adipose Tissue in HIV Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue CONFORM: Rotational Fractional Resection for Submental Contouring Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy TH9507 in Patients With HIV-Associated Lipodystrophy TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Energy Expenditure of People Living With HIV/AIDS Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Egrifta Replacement and Sleep Disordered Breathing Clinical Trial to Determine the Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients Low Energy Diet and Familial Partial Lipodystrophy Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Role of the Autonomic Nervous System in HIV-Lipodystrophy Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome Therapeutic Approaches to HAART-Induced Lipodystrophy Different Surgical Modalities for Thigh Lipodystrophy Including Liposuction,Thigh Lift and Liposuction Assisted Thigh Lift Leptin to Treat Lipodystrophy Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat Corticosteroid-induced Lipodystrophy and Adipokines Short-term Effects of Leptin in People With Lipodystrophy Leptin to Treat Lipodystrophy Lipodystrophy Connect Patient Registry An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy

Brief Title

Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients

Official Title

A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS

Brief Summary

      The primary objective of the study is to determine if Serostim® 4 mg administered daily for
      12 weeks as treatment for the abnormal fat accumulation and distribution associated with
      HIV-associated Adipose Redistribution Syndrome (HARS) reduces Visceral Adipose Tissue (VAT,
      measured by CT scan) more effectively than placebo.
    


Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12

Secondary Outcome

 Treatment Period I: Change From Baseline in Trunk Fat at Week 12

Condition

HIV Infections

Intervention

Placebo

Study Arms / Comparison Groups

 Period I: Placebo
Description:  Subjects will receive placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

326

Start Date

May 28, 2004

Completion Date

September 28, 2005

Primary Completion Date

September 28, 2005

Eligibility Criteria

        Inclusion Criteria:

          1. Have written laboratory documentation of an HIV infection by one of the following
             methods:

               -  Detectable viral load measured by polymerase chain reaction (PCR) amplification,
                  branched chain DNA (bDNA) signal amplification or the presence of p24 antigen.

               -  Presence of HIV antibodies confirmed by either Western blot or immunofluorescence
                  assay.

             Written laboratory documentation of an HIV infection must be obtained prior to
             randomization. In the absence of documented historical confirmation, an assay of HIV
             antibodies will be included in the Screening Laboratory Panel. Results will be
             confirmed with a Western Blot.

          2. Have evidence of excess abdominal adipose deposition when measured by the
             anthropometric methodology, using the following cut off values:

               -  Men: Waist circumference >88.2 cm AND waist: hip ratio >= 0.95.

               -  Women: Waist circumference >75.3 cm AND waist: hip ratio >= 0.9.

          3. Are taking antiretroviral medication(s) which is (are) approved or is (are) available
             under a Treatment IND. The regimen must have remained stable for 30 days prior to
             study entry. Subjects must also agree not to discontinue or to change their regimen
             for the duration of the study except as judged medically necessary.

          4. Have parameter values less than the following limits (using results from the central
             laboratory):

               -  AST, ALT, and amylase <= 3 times the upper limit of normal (Screening).

               -  Fasting triglycerides <= 1,000 mg/dL (Screening).

               -  Fasting glucose <110 mg/dL (Screening).

               -  Two-hour (120 minute) glucose <140 mg/dL (Screening).

          5. Weight >= 36 kg (79.3 lb)

          6. Be between 18 and 60 years of age (inclusive) unless local law dictates different
             limits.

          7. Sufficiently literate in English to be able to comprehend and complete the Quality of
             Life Questionnaire.

          8. Willing and able to comply with the protocol for the duration of the study.

          9. Have voluntarily provided written informed consent (with subject authorization under
             HIPAA), prior to performing any study-related procedure that is not part of normal
             medical care, and with the understanding that the subject may withdraw consent at any
             time without prejudice to future medical care.

         10. Female subjects must:

               1. Be post menopausal (>= 1 year) or surgically sterilized (i.e., have undergone
                  tubal ligation or hysterectomy)

                  or

               2. Use a contraceptive method for the duration of the study such as:

                    -  Hormonal contraceptive

                    -  Intra uterine device

                    -  Diaphragm with spermicide, or condom with spermicide.

                  And

               3. Must be neither pregnant nor breast feeding.

               4. Confirmation that female subjects of childbearing potential are not pregnant must
                  be established by a negative beta-hCG serum pregnancy test during the 14-day
                  screening period prior to Study Day 1. If the beta-hCG serum pregnancy test is
                  performed more than 7 days prior to Study Day 1, a urine pregnancy test must be
                  performed by the site laboratory on Study Day 1 to confirm a negative test
                  result.

        Exclusion Criteria:

          1. Have an active AIDS-defining opportunistic complication (OC) as defined by the CDC or
             have had an untreated or suspected serious systemic infection, or have had a
             persistent fever >= 101°F (38.3°C) during the 30 days prior to study entry.

          2. Any active or past history of malignancy, except for localized cutaneous Kaposi's
             sarcoma (fewer than 10 lesions, none of which are larger than 2 cm, and not on active
             therapy). Such exceptions must be confirmed in writing by the Serono Study Director.

          3. Have a CNS mass or active CNS process associated with neurological findings.

          4. Have unstable or untreated hypertension, defined as >= 140/90 mm Hg at the time of the
             Screening Visit, and/or have initiated or changed antihypertensive therapy in the 30
             days prior to Study Day 1.

          5. Have an acute critical illness treated in an intensive care unit, e.g., due to
             complications following open heart or abdominal surgery, multiple accidental trauma,
             or acute respiratory failure.

          6. Have a recent history of sleep apnea or intermittent upper respiratory obstruction.

          7. Have any condition, which interferes with informed consent or protocol compliance
             including, but not limited to, active substance abuse and/or dementia.

          8. Are unable to comply with the Concomitant Therapy restrictions including:

               -  therapy for obesity including therapy with anorexigenic or fat reducing drugs

               -  anti-diabetic or insulin sensitizing medications

               -  systemic glucocorticoids

               -  systemic chemotherapy, interferon or radiation therapy treatment

               -  androgenic agents including, but not limited to testosterone, nandrolone,
                  oxandrolone, oxymetholone, etc. (testosterone replacement therapy for
                  hypogonadism is the exception to this exclusion and will be allowed if started >
                  30 days prior to Study Day 1)

               -  progestational agents, unless used for oral contraception or post-menopausal
                  hormone replacement therapy

               -  appetite stimulants

               -  investigational agents, unless approved in advance by the study medical director.
                  Specifically, experimental antiretroviral agents are disallowed, unless available
                  under a treatment IND or expanded access program (30 days).

               -  Liposuction or other elective plastic surgery

               -  AIDS wasting therapy or prior growth hormone treatment other than study drug (for
                  12 months prior to the screening visit)

          9. Have ever been diagnosed with any of the following conditions:

               -  Pancreatitis

               -  Carpal tunnel syndrome (unless resolved by surgical release)

               -  Diabetes mellitus

               -  Angina pectoris

               -  Coronary artery disease

               -  Any disorder associated with moderate to severe edema (e.g., ascites, nephrotic
                  syndrome, congestive heart failure, lymphedema).

         10. Allergy or hypersensitivity to growth hormone.

         11. Are participating in any other clinical studies.

        In order to participate in this trial a subject must meet all of the inclusion and
        exclusion criteria specified above. Requests for protocol exceptions/exemptions must come
        from a participating, fully initiated site at which a prospective patient has consented to
        undergo screening. Exceptions/exemptions are only allowed by the Trial Director. There is
        no program in place to allow drug for a single patient IND, or for an expanded access
        protocol. This statement holds true for both children and adults.
      

Gender

All

Ages

18 Years - 60 Years

Accepts Healthy Volunteers

No

Contacts

Medical Responsible, , 

Location Countries

Canada

Location Countries

Canada

Administrative Informations


NCT ID

NCT00082628

Organization ID

24380


Responsible Party

Sponsor

Study Sponsor

EMD Serono


Study Sponsor

Medical Responsible, Study Director, EMD Serono Inc., a business of Merck KGaA, Darmstadt, Germany


Verification Date

September 2017